Idaho v. Daicel Chemical Co. et al., No. 30379 (Idaho 2005)
State filed suit on behalf of indirect purchasers after federal guilty pleas by sorbates manufacturers. Case dismissed on grounds that Idaho Competition Act which permitted recovery by indirect purchasers was not enacted until 2000 and did not permit retroactive application.
U.S. et al. v. EchoStar Communications, Corp., et al. No. 1:02CV02138 (D.D.C.)
Federal and State action to enjoin merger of two direct broadcast satellite (DBS) companies. The merging parties abandoned their merger agreement
Connecticut v. Mylan Laboratories, Inc. (In re Lorazepam & Clorazepate Antitrust Litigation), MDL No. 1290 (D.D.C. June 15, 2000) 205 F.R.D. 369 (D.D.C. 2002); No. 98 CV 3115 (D.D.C. 2000) – complaint
Plaintiff States alleged that Mylan Laboratories, Inc.(Mylan) and other drug companies entered into illegal agreements to monopolize the market for certain generic anti-anxiety drugs.
Texas v. Zeneca, 1997 U.S. Dist. LEXIS 13153 (N.D. Tex. 1997)
States sought an injunction and monetary damages from Zeneca, Inc. (Zeneca), alleging that the company conspired with distributors of its crop protection chemicals to maintain the resale price of the chemicals.
Utah v. Phillips Petroleum Co. and Conoco, Inc., No. 2 02 CV-0982 (D. Utah 2002)
Plaintiff States sought to enjoin Phillips Petroleum Co. (Phillips Petroleum) and Conoco, Inc. (Conoco) from entering into a merger agreement, arguing that the merger would substantially impair competition for refining bulk supply and sale of gasoline.
Texas v. Conoco, Inc. and Phillips Petroleum Company (D.C. TX, 2002); Missouri v. Conoco Inc., No. 02-4190-CV-W-NKC (W.D. Mo. Oct. 2,
Plaintiff States sought to enjoin Conoco, Inc. (Conoco) and Phillips Petroleum Company (Phillips Petroleum) from consummating their merger, arguing that the merger would significantly impair competition for natural gas gathering and for natural gas liquids fractionation.
In re Clozapine Antitrust Litigation, MDL No. 874 (N.D. Ill. 1991)
Plaintiff States sought monetary damages and injunctive relief against Sandoz Pharmaceuticals Corporation (Sandoz), alleging the company unlawfully required those who purchased its drug, Clozapine, to also purchase distribution and patient monitoring services from Sandoz.
In re Compact Disc Minimum Advertised Price Antitrust Litigation MDL No. 1361 (D. Me. 2002) MDL-1391; No. 00-CIV-5853 (BSJ) (S.D.N.Y Aug. 8, 2000) (complaint)
Plaintiff States sought damages and injunctive relief, alleging that Defendant CD distributors unlawfully conspired to implement stringent minimum advertised price (MAP) policies in violation of antitrust laws.
In re: Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.) (see also Ohio v. Bristol Myers Squibb
Plaintiff States sought damages and injunctive relief, alleging that Bristol-Myers Squibb Co. (BMS) attempted to maintain an unlawful monopoly on buspirone hydrochloride, a medication used to treat generalized anxiety. In settling, BMS agreed to a stipulated injunction and to reimburse consumers and state and local public entities for overcharges. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlement, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.
In re Disposable Contact Lens Antitrust Litigation, 2001-1 Trade Cas. (CCH) & 73,150
Plaintiff States sought damages and injunctive relief against the three major contact lens makers and the American Optometric Association. The States alleged that defendants conspired to cut mail order companies and pharmacies out of the market for replacement contact lenses.
